Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tarcsa, E.
Right arrow Articles by Steinert, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarcsa, E.
Right arrow Articles by Steinert, P. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 48, Issue of November 29, 1996 pp. 30709-30716
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Protein Unfolding by Peptidylarginine Deiminase
SUBSTRATE SPECIFICITY AND STRUCTURAL RELATIONSHIPS OF THE NATURAL SUBSTRATES TRICHOHYALIN AND FILAGGRIN*

(Received for publication, September 13, 1995, and in revised form, May 28, 1996)

Edit Tarcsa , Lyuben N. Marekov , Giampiero Mei Dagger , Gerry Melino Dagger , Seung-Chul Lee § and Peter M. Steinert

From the Laboratory of Skin Biology, NIAMS, National Institutes of Health, Bethesda, Maryland 20892, Dagger  Istituto Dermopatico dell'Immacolata, Biochemistry Laboratories at Department of Experimental Medicine and Biochemical Sciences, University Tor Vergata, Rome 00133, and Department of Biology, University of L'Aquila, L'Aquila 67100, Italy

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Peptidylarginine deiminases, which are commonly found in mammalian cells, catalyze the deimination of protein-bound arginine residues to citrullines. However, very little is known about their substrate requirements and the significance or consequences of this postsynthetic modification. We have explored this reaction in vitro with two known substrates filaggrin and trichohyalin. First, the degree and rate of modification of arginines to citrullines directly correlates with the structural order of the substrate. In filaggrin, which has little structural order, the reaction proceeded rapidly to >95% completion. However, in the highly alpha -helical protein trichohyalin, the reaction proceeded slowly to about 25% and could be forced to a maximum of about 65%. Second, the rate and degree of modification depends on the sequence location of the target arginines. Third, we show by gel electrophoresis, circular dichroism, and fluorescence spectroscopy that the reaction interferes with organized protein structure: the net formation of >= 10% citrulline results in protein denaturation. Cyanate modification of the lysines in model alpha -helix-rich proteins to homocitrullines also results in loss of organized structure. These data suggest that the ureido group on the citrulline formed by the peptidylarginine deiminase enzyme modification functions to unfold proteins due to decrease in net charge, loss of potential ionic bonds, and interference with H bonds.


INTRODUCTION

Peptidylarginine deiminases (PAD)1 (protein-arginine deiminase, protein-L-arginine iminohydrolase, EC 3.5.3.15) are a family of Ca2+-dependent enzymes that catalyze the post-translational deimination of protein-bound arginine residues to citrullines (1, 2, 3, 4, 5, 6, 7). Biochemical studies have revealed that there are two or possibly three different types of PAD enzymes (8, 9, 10). The type 1 enzyme is found in the epidermis and to a lesser extent in the uterus. Type 2 enzyme is expressed in muscle, brain, uterus, spinal cord, pancreas, spleen, salivary gland, stomach, thymus, pituitary, submaxillary gland, etc. Type 3 enzyme is present in hair follicle tissue and in the epidermis. The rat and mouse type 2 (11, 12) and part of the mouse uterus type 1 (13) enzymes have been cloned and sequenced. A recent report indicated that the sequence of the type 3 enzyme is highly homologous to the type 2 enzyme (14).

Little is known about the precise function(s) or target substrates of the PAD enzyme in most tissues. PAD deimination was suggested to modify the action of trypsin-like enzymes (4) and trypsin inhibitors (15, 16), interfere with intermediate filament (IF) assembly (17, 18, 19) and play a role in rapid cellular turnover in tissues of secretory activity (9). However, the physiological significance of each of these has not been established.

On the other hand, there are two well documented protein substrates of PAD. One is the filaggrin, which is present only in orthokeratinizing epidermis. Filaggrin can bundle keratin IF into tight arrays in vitro and in vivo (20) due to ionic interactions of its basic charges with the negatively charged keratin IF (21). Filaggrin is largely (22) or partly (19) deiminated in differentiated human stratum corneum cells, rendering it neutral in charge. The second known substrate protein is trichohyalin (THH), which is a major differentiation product of the inner root sheath cells of the hair follicle, and of the medulla in the hair fiber and related structures such as porcupine quills (23, 24, 25, 26). THH is also expressed to a lesser extent in interfollicular normal human epidermis, and foreskin epidermis (27, 28). Isolated sheep (25, 29), human, and pig (27, 30) THH are highly insoluble proteins. Secondary structure predictions showed that they are likely to adopt a single-stranded alpha -helical structure (31). A variety of studies have now established that THH is a target substrate protein for deimination by PAD in hair follicle cells (3, 19, 32, 33, 34, 35, 36).

However, the details of the reaction of PAD with filaggrin and THH or other substrates remain unclear. Moreover, the function of the PAD modification events in these tissues remains unknown. In this study, we have explored the substrate specificity of the type 2 PAD using as substrates mouse filaggrin, human THH, and other model peptides of related structures. Our data reveal certain sequence and substrate structural requirements for the enzyme and, for the first time, the consequences of its action, which provide insights into its function in the skin.


EXPERIMENTAL PROCEDURES

Materials

The following were purchased: type 2 rabbit skeletal muscle PAD (PanVera Corp., Madison WI); sequencing grade Asp-N protease (Boehringer Mannheim); precast Tris-glycine, Tricine, and isoelectric focusing (pH 3-7 and 3-10) gels (Novex, San Diego, CA); horse heart myoglobin, protamine sulfate, and a synthetic copolymer polypeptide of average composition alanine6-lysine5-glutamate2-tyrosine1 (20,000-50,000 molecular weight; Sigma). Mouse filaggrin was isolated and purified as described (20, 21). Several synthetic peptides (Table I) were purified by HPLC and quantitated by amino acid analysis.

Table I.

Extents of modification of arginines in synthetic peptides and peptides derived from proteins

The numbers above the arginine residues show the approximate percentage converted to citrulline. For THH-8 peptides, the sequences shown are representative of >80% of the total protein. In this case, most peptides were not sequenced to completion; the lowercase letters define the remainder of the sequence of the long peptide, as ascertained by amino acid analysis. Peptide 1 was sequenced from intact THH-8
Origin (Ref.) Sequence Secondary/Structure

                            9595          9595
Peptide from mouse filaggrin       DSQVHSGVQVEGRRGHSSSANRRA
                      5            908090                0    0    90
Peptides from human THH-8   1.  PEEEQLEREEQKEAKRRDRKSQEEKQLLREEREEKR
      8070  9090
      RRQETRDRKSQEEKQLL...
        85    5          9560  0 50
  2.  DRKFREEEQQVRRQERERKFLEEEQQlrqerhrkfr
              eeeqllqereeqqlhrqer
       80    0      95        70
  3.  DRKFREQELRSQEPERKFLEEEqqlhrqqrqrkflq
              eeqqlrrqergqqrq
        85    0        95    0
  4.  DRKFREEEQLRQEREEQQlsrqer
                9585
  5.  DEQQLRRQEGQqqlrqe
                      0
  6.  DEQLLQEREEQqlhrqer
        90                9575  0
  7.  DRKFLEEEPQLRRQEREqqlrh
        85    0
  8.  DRKFREEEQLLQEGEEQqlrrqer
              95
  9.  DGKYRWEEEQLQLEEQlqleeqeqrlrqer
        80  95
10.  DRQYRAEEQFATQEKsrreeqelwqeeeqkrrqere
                rklreehirrqqkeerhr
Synthetic peptides             95    95    95    95
  Mimetic filaggrin (Mack et al., 1993)         SGSRSGSRSGSRSGSRSGS Random coil (beta -turn motifs); unchanged
        5
  Human keratin 1 subdomain 1A (Chipev et al., 1993)         REQIKSLNNGFASFIDK  alpha -Helical; unchanged
        50              85          8585                              40
  Human keratin 10 1A subdomain (Zhou et al., 1988)         GRVTMQNLNDRLASYLDRVRALEESNYELEGKIKERYD  alpha -Helical to disordered structure
        0  9595    5          9570  5        95
  Human THH (Lee et al., 1993)         RQERDRKFREEEQQLRRQEREEQQLR  alpha -Helical to disordered structure
        80  9595  70
  Mimetic THH         GRQERDRKFREEEQ Random coil; unchanged
        0    100907050  100859595
        REQQLRRQERREQQLRRQERDRKF  alpha -Helical to disordered structure

Analytical Methods

Samples were subjected to acid hydrolysis (5.7 M HCl, 110 °C, 22 h, in vacuo), and their amino acid compositions were determined on a Beckman 6300 amino acid analyzer. The amount of citrulline was corrected for hydrolytic losses to ornithine. Citrulline and ornithine eluted at 15.7 and 50.1 min, near glutamic acid and lysine, respectively. Protein concentrations of samples were determined according to Bradford (37), and by amino acid analysis. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was done according to Laemmli (38).

Expression and Purification of Human Trichohyalin Domain 8

The construct of THH-8 (residues 1250-1849 predicted by secondary structure analysis) for expression was made by polymerase chain reaction with primers from the sequences of domain 8 (31), and confirmed by sequencing. The ATG start and TGA stop codons were inserted at the positive and negative polymerase chain reaction primers, respectively. This construct was cloned into the pET-11a vector (Novagen, Madison, WI) (39). The vector was transformed into the BL 21 E. coli strain, and bacteria (1-5-liter cultures) were grown in Terrific Broth (Sigma; modified, supplemented with 10 g/liter glucose and 50 µg/ml carbenicillin) until A600 nm = 1.2. Protein expression was induced with 1 mM isopropyl-2-thio-beta -D-galactopyranoside for 3 h (final A600 nm = 2.5). Bacterial pellets (10,000 × g, 30 min) were lysed and DNase-digested as described (40). The inclusion bodies were isolated by centrifugation (27,000 × g, 5 min) and washed in 50 mM Tris-HCl (pH 8.0) 1 mM EDTA, 1% Triton X-100 several times. The pellet was solubilized in 8 M urea, 20 mM Tris-HCl (pH 8.8), loaded, and chromatographed at a flow rate of 15 ml/h on a Sepharose Q Fast Flow column equilibrated in this buffer. The column was then washed in the same buffer without urea, and the THH-8 was eluted with a linear gradient of 0-1.0 M NaCl. THH-8 was identified by Western blotting with poly- and monoclonal anti-pig THH antibodies (27). The purity and concentrations of the combined fractions was determined by amino acid analysis.

Modifications of Proteins and Peptides with PAD

THH-8 (50 µg/ml) was incubated with PAD at 37 °C at different enzyme:substrate molar ratios (between 1:1000 and 10:1) in a buffer of 20 mM Tris-HCl (pH 8.8), 0.3 M NaCl, 1 mM EDTA, 10 mM dithiothreitol, 5 mM CaCl2, and the reaction was terminated as required by the addition of EDTA (10 mM final concentration). To determine the extent of reaction (i.e. appearance of citrulline), samples obtained at low enzyme:substrate ratios were acid-hydrolyzed directly for amino acid analysis. Control experiments showed that the PAD enzyme alone does not generate citrulline during reaction. When high enzyme:substrate ratios were used, the reaction products were first resolved on 10% Tricine gels (Novex), transferred onto polyvinylidene difluoride membranes, and after a brief staining with Coomassie Brilliant Blue, the appropriate THH bands were cut out and hydrolyzed. Aliquots of the samples were resolved on 8% SDS-PAGE, and either pH 3-7 or 3-10 isoelectric focusing gels. Mouse filaggrin (10 µM) was incubated as described for THH-8 at an enzyme:substrate molar ratio of 1:1000 in the Tris buffer at pH 8.0. The degree of modification was likewise determined by amino acid analysis. Synthetic peptides were deiminated at an enzyme:arginine molar ratio of 1: 40,000 at pH 8.0 at 37 °C for 3 h. The products were separated by HPLC on a reverse phase column prior to amino acid analysis.

Separation of Peptides From THH-8 and Filaggrin

Unmodified and modified THH-8 and filaggrin samples in 0.1 M NH4HCO3 were digested with Asp-N protease at a ratio of 1:2,000 (by weight) at 23 °C for up to 18 h. The fragments were separated by HPLC on a narrow bore reverse phase column (218TP52) (Vydac, Hesperia, CA) using a 10-60% acetonitrile gradient containing 0.08% trifluoracetic acid in 50 min at 0.23 ml/min flow rate. The eluted peaks were dried, and their amino acid compositions were determined and sequenced.

Peptide Microsequencing

Peptides were covalently attached to a Sequelon-AA polyvinylidene difluoride solid support (Millipore, Bedford, MA) and sequenced by Edman degradation in a LF3000 gas phase sequencer (Porton) using the manufacturer's recommended procedure number 39. PTH-derivatives were separated by on-line reverse-phase HPLC (using 3.5% tetrahydrofuran in buffer A; Ref. 41) with System Gold software. PTH-citrulline eluted at 6.1 min, immediately after PTH-threonine.

Chemical Modification of Proteins with Cyanate

Samples of THH-8 (0.14 mg/ml), horse heart myoglobin (0.7 mg/ml), and a commercial random synthetic polypeptide (molecular weight 20,000-50,000) of average composition alanine6-lysine5-glutamate2-tyrosine1 (0.5 mg/ml) were reacted with potassium cyanate for up to 24 h to convert lysine residues to homocitrullines (42). After reaction, the protein samples were equilibrated by dialysis into 10 mM Tris-HCl (pH 7.5). The extent of reaction was followed by acid hydrolysis, although 35% of the homocitrulline was converted back to lysine under the conditions used (42). Homocitrulline eluted from the Analyser column at 26.0 min.

Physicochemical Measurements

THH-8 (0.05-0.1 mg/ml), mouse filaggrin (0.2 mg/ml), myoglobin (0.5 mg/ml), or copolymer polypeptide (0.35 mg/ml) solutions were equilibrated into the same buffer as used for the PAD reaction. Steady state fluorescence excitation and emission spectra were recorded on a photon-counting spectrofluorometer (Fluoromax Instruments, Paris, France). The bandwidths of excitation and emission monochromators were in the range of 2-4 nm. In all fluorescence experiments, spectra were corrected for Raman contributions by buffer base-line subtraction. Absorption and circular dichroism (CD) measurements were carried out using a Jasco Uvidec 650 spectrophotomer and Jasco 600 and 700 spectropolarimeters, respectively. In both cases, 0.1-cm quartz cuvettes were used. The sample holders were thermostated before and during measurements, using external circulation. Protein concentrations were measured by amino acid analyses to calculate molar ellipticity values for estimation of helix contents. In addition, alpha -helical contents were routinely estimated by use of curve-fitting algorithms from the shape of the spectra, especially in the case of the copolymer polypeptide of heterogeneous molecular weight. The two methods yielded identical estimates.


RESULTS AND DISCUSSION

To date, studies with the PAD enzyme have utilized mostly model peptide substrates. The purpose of the present study was to explore the specificity and structural requirements of the PAD enzyme using the known in vivo substrate proteins mouse filaggrin and a more soluble cloned portion of human THH (THH-8). For the enzyme, we have used the commercially available type 2 enzyme from rabbit skeletal muscle. While there are minor differences in the antigenicity and apparent molecular weights of the type 2 ("ubiquitous") and 3 ("hair follicle") enzymes, they have been reported to have essentially identical substrate specificities (8, 9, 14).

PAD Modification of Mouse Filaggrin

Mouse filaggrin (30 kDa) contains 16% arginine (40 residues/mol) (43). By amino acid analysis, an average of 95% were deiminated to citrullines within 3 h using an enzyme:substrate ratio of 1:1000 (Fig. 1A), so that the total citrulline content was >15%. To determine whether the 95% conversion meant that all arginines were equally modified or whether ~2 were not modified at all, the filaggrin sample was digested with Asp-N protease, and the 15 fragments encompassing the entire sequence were separated by reverse-phase HPLC. The peptides were subjected to acid hydrolysis, and their amino acid compositions were determined. In all fragments ~95% of the arginine was modified. In confirmation, one fragment containing 4 arginines (Table I) was directly sequenced by Edman degradation. At each expected arginine residue position, >95% citrulline was recovered. The partially and fully modified filaggrin migrated considerably more slowly by SDS-gel electrophoresis (Fig. 1B). While this phenomenon has not been described previously with model protein substrates, two studies have reported progressive decreases in the mobility of human (19) and rat (22) filaggrins partially deiminated in vivo.


Fig. 1. PAD deimination of mouse filaggrin. A, conversion rate of arginines to citrullines using a PAD:filaggrin ratio of 1:1000. The data are the averages of three experiments. B, SDS-PAGE for 0, 10, 20, 40, 60, 120, 180, and 1080 min, respectively.
[View Larger Version of this Image (33K GIF file)]


Expression and Purification of Human THH-8

Although THH can be easily purified from hair follicle tissue (25) or pig tongue epithelium (30) because of its extraordinary insolubility, this precludes its use in in vitro enzymatic reactions. Instead, we have expressed in bacteria domain 8, the largest domain representing about 30% of human THH. This domain consists of numerous irregular peptide repeats of about 26 residues that are typical of the entire human THH sequence (31). The 80-kDa protein was expressed in E. coli and purified to homogeneity (Fig. 2, inset, lane 1). Its amino acid composition is as expected from its known sequence (including 137 arginines, 22.8%), and is ~86% alpha -helical as determined by CD (see Fig. 5B, line 1). Since this result is exactly as predicted for this THH sequence and is consistent with the available data for native pig tongue THH (31), the data indicate that the bacterially expressed protein had properly adopted the native structural configuration. The THH-8 cross-reacts with existing monoclonal (Fig. 2, inset, lane 2) and polyclonal (data not shown) antibodies (27). In the pH 8.8 buffer, its solubility was limited to ~100 µg/ml.


Fig. 2. Purification of human THH-8. Human recombinant THH-8 was obtained as an enriched fraction from urea dissolution of the bacterial inclusion bodies, and then recovered in pure form by chromatography on a Sepharose Q Fast Flow column (arrow). Inset, SDS-PAGE of samples: lane 1, Coommassie Brilliant Blue staining; lane 2, Western blot using a monoclonal anti-pig THH antibody.
[View Larger Version of this Image (16K GIF file)]



Fig. 5. Circular dichroism shows that PAD promotes loss of secondary structure in filaggrin and THH-8. A, CD spectra of mouse filaggrin (line 1) and of filaggrin in which >95% of the arginines had been modified to citrullines by PAD (line 2). B, CD spectra of THH-8 (line 1) or of THH-8 after ~25% (line 2), ~40% (line 3), and ~65% (line 4) conversion of arginines to citrullines by PAD. C, urea unfolding titration curves of THH-8 by urea calculated on the basis of the CD signal obtained at 222 nm. The arrows on the left indicate the corresponding values obtained with PAD from line 3 (PAD 1) and line 4 (PAD 2) of panel B.
[View Larger Version of this Image (20K GIF file)]


PAD Modification of Human THH-8

The conversion of arginines to citrullines with time as a function of enzyme concentration was assayed by amino acid analysis and was markedly slower in THH-8 than for filaggrin. Using the low enzyme:substrate ratios used with filaggrin (1:1000), very little modification occurred (Fig. 3A, line 1). At ratios of 1:100-1:50, about 20-25% of the arginine content was modified (line 2), but a maximum of up to about 65% could be achieved at higher ratios (up to 10:1) (line 3). As was found for filaggrin, the migration of the modified THH-8 on SDS gels was reduced in a gradual fashion so that its Mapp was about 160 kDa (Fig. 3B). By isoelectric focusing, bands of progressively more acidic charge were seen (Fig. 3C), from pI ~6.5 for unmodified THH-8, which only enters the gel poorly, to pI 4.8, commensurate with the expected loss of arginine. We also noted that partially to maximally modified THH-8 samples became more soluble (>0.5 mg/ml).


Fig. 3. PAD deimination of human THH-8. A, conversion rate of arginines to citrullines with PAD:THH-8 molar ratios of 1:1000 (line 1), 1:100-1:50 (line 2), or 1:30-10:1 (line 3). The data are the averages of three to five experiments. B, SDS-PAGE of a 1:30 reaction for 0, 5, 10, 20, 40, 60, 120, 300, and 1080 min, respectively, and stained with Coomassie Brilliant Blue. M, molecular weight markers of indicated sizes. C, as in B, except same samples were resolved by isoelectric focusing on a pH 3-7 gel. S, standard markers (Bio-Rad) of indicated pI values.
[View Larger Version of this Image (38K GIF file)]


We next wanted to determine why the modification of THH-8 proceeded to only about 65%. Aliquots of unmodified and maximally modified THH-8 were digested with Asp-N, and the fragments were separated on reverse phase HPLC. In the latter, the elution times of the peaks were largely unchanged, probably because most peptides were relatively long (>20 residues), but the peaks became more broad (data not shown). This may be because each peak constituted a mixture of forms of a single peptide whose several arginines were modified to varying extents. By amino acid analyses, most peptides showed 30-70% modification. Many peptides were then partially or completely sequenced, encompassing about 40% of the THH-8 protein (see Table I for partial list). Due to the highly repetitive nature of THH-8, these are representative of >80% the protein. Indeed, we found that the citrulline contents varied across the broad peptide peaks. However, in general, most of the arginines were converted to citrulline by >75%, except those arginines followed by a glutamic acid residue, which were only slightly modified at <= 5%. Since about one-third of the arginines are followed by glutamic acid residues, this provides a simple explanation for the observed maximal extent of modification. In the special cases of two (Table I, peptides 2, 5, and 7) or three (peptide 1) consecutive arginines in THH-8, the first was completely but the second and/or third were modified less efficiently. In addition, intact modified THH-8 was sequenced from its amino terminus (Table I, peptide 1) to show that arginines followed by aspartic acid residues were modified to near completion.

Progressive Decreases in The Mobilities of Filaggrin and THH-8 after PAD Modification May Be Due to Alterations of Their Conformation and Charge

Changes in mobilities of proteins in SDS fields are often due to changes in conformation and/or charge (44). To further explore this issue, we included 8 M urea in the SDS gel and the sample buffer prior to boiling. In both cases, the unmodified as well as partially modified filaggrin (Fig. 4A) and THH-8 (Fig. 4B) samples all migrated at the decreased rates of ~60 or ~160 kDa, respectively, close to the modified forms. Both of these proteins have unusual structures. Filaggrin is thought to possess a beta -turn secondary structure (21) so that the molecule adopts a compact form, which would be expected to be unfolded by urea into a larger molecular volume. THH-8, like intact THH itself, is thought to form a single-stranded alpha -helix in which successive turns of the helix are stabilized by intrachain ionic bonds (31, 45) to form an elongated rodlike shape, which might not be completely unfolded by SDS. In these cases, urea may be a more efficient protein denaturant than SDS. Indeed, numerous other reports have documented that SDS denaturates some proteins incompletely (44, 46, 47). When arginine is converted to citrulline, the guanidino group is replaced by a ureido group. This modification would be expected to destroy many potential salt bonds and interfere with H bonds, which could thus destabilize the protein structures, resulting in unfolding. Thus we speculate that the progressive mobility decreases caused by partial PAD modification may be related to progressive unfolding, i.e. maximal modification of filaggrin and THH-8 by PAD may result in changes in structure that are comparable with denaturation by urea.


Fig. 4. SDS-PAGE of unmodified or partially modified filaggrin and THH-8 in the presence of 8 M urea causes anomalous migration. Samples from Fig. 1B (A) and Fig. 3C (B) (except the samples taken at 1080 min) were made to 8 M urea before boiling in SDS sample buffer, and run on standard Laemmli gels (8% gel) except that the gel also contained ~8 M urea.
[View Larger Version of this Image (72K GIF file)]


In addition, the mobility changes may be due to changes in charge of the target protein. This is especially true of arginine-rich basic proteins, and proteins rendered neutral or acidic in charge following chemical modification (48, 49, 50). For example, the mutation of a single arginine residue resulted in significantly decreased mobility of a protein (51). It is possible that the net gain of many more acidic charges on the proteins arising from loss of arginines may in effect explode the proteins due to adverse charge interactions. Consistent with this, we could modify 75% of the arginines of protamine sulfate to generate a citrulline content of ~50%. In this case, the protein became neutral in charge, soluble in SDS, and migrated with an apparent molecular weight twice its expected size (data not shown). Mobility changes were also seen with histones (final citrulline contents of up to ~10%).

Thus in the cases of the arginine-rich proteins THH-8 and filaggrin, the unusual mobility changes induced by PAD modification may be due to a combination of structure and charge changes (44, 51). Further studies on other model proteins containing high contents of arginine, lysine, and acidic residues seem desirable to resolve these issues.

Biophysical Measurements Confirm That PAD Modification Reduces the Degree of Structural Order of Proteins

The postulated structural consequences of the PAD reaction were examined directly using biophysical analyses. As expected (21), by CD, filaggrin is mostly beta -turn in structure (Fig. 5A, line 1), but after complete modification, the spectrum becomes flat (line 2), indicative of a loss of organized structure (52, 53, 54). On the other hand, THH-8 is ~86% alpha -helical (Fig. 5B, line 1), as predicted from its sequence, and it is slightly more ordered than observed for intact native pig tongue THH (31). Conversion of 25% (line 2), 40% (line 3), or 65% (line 4) of its arginines, generating citrulline contents of ~5.5%, 9%, and 15%, reduced its alpha -helical contents to ~60%, 35%, and to no organized structure, respectively. This loss of alpha -helicity observed in lines 3 and 4 is comparable with denaturation of the THH-8 by 2.5 M or 4.5 M urea, respectively (Fig. 5C).

We also used fluorescence spectroscopy. The spectrum of THH-8 upon excitation at 280 nm (to visualize both tyrosines and tryptophans) is blue-shifted, and the peak at 312 nm suggests that the two tryptophan residues are buried within the protein structure (Fig. 6A, solid line). However, following maximal modification by PAD, the red shift in the fluorescence spectrum toward longer wavelengths (dotted line) is similar to that of THH-8 fully denatured in 6 M urea (dashed line). These data indicate that upon maximal modification by PAD, the two tryptophans have become exposed and thus freely mobile, which is consistent with the concept of loss of organized structure.


Fig. 6. Fluorescence spectroscopy shows that PAD promotes unraveling of THH-8 structure. A, steady state fluorescence spectra of THH-8 (solid line), THH-8 maximally modified by PAD (dotted line), and THH-8 denatured by 6 M urea (dashed line). Excitation was at 280 nm. B, anisotropy measurements were made in the cuvette after the addition of increasing aliquots of PAD enzyme, followed by 60-min reaction intervals (arrows). Based on amino acid analyses, all protein remained in solution. The three additions caused ~15%, 30%, and 45% modification, respectively.
[View Larger Version of this Image (19K GIF file)]


Furthermore, steady state fluorescence anisotropy measurements were made (Fig. 6B). On addition of increasing amounts of PAD enzyme to the cuvette containing the THH-8 solution, the anisotropy decreased from 0.21 (unmodified THH-8) to less than 0.15 in protein in which ~40% of the arginines had been modified (~11% citrulline content). This decrease clearly indicates the absence of protein dimerization, as also suggested by the SDS-PAGE data (Figs. 1 and 3), and confirms that the protein had become unfolded by the PAD modification reaction.

Introduction of Homocitrullines Also Interferes with Protein Structures

The foregoing data suggest that the modification of arginines to citrullines results in a progressive unfolding of the proteins equivalent to that obtained with >= 4.5 M urea. One possible explanation for this phenomenon is that the substituted urea side chain of citrulline interferes with ionic and H-bonding interactions. To test this hypothesis, we inserted homocitrulline into proteins by chemical conversion of the epsilon -NH2 groups of their lysine side chains with cyanate. We used three proteins of widely differing lysine contents but which have highly ordered structures: THH-8 (5.5% lysine, 86% alpha -helix), intact myoglobin (12.7% lysine, 70% alpha -helix), and a commercially available random copolymer polypeptide (35.7% lysine, 90% alpha -helix). Reaction with cyanate for up to 24 h resulted in high degrees of conversion of lysines to homocitrullines and retention of their high solubilities, based on amino acid analyses (data not shown). By CD, the alpha -helical content of THH-8 was estimated to have been reduced from 86% to ~60% (1.6% homocitrulline), ~20% (3% homocitrulline), and to ~10% (4% homocitrulline) (Fig. 7A, lines 1-4, respectively). In the case of the lysine-rich synthetic copolymer peptide, the alpha -helical content was reduced from 90% to ~40% (5% homocitrulline), ~10% (17% homocitrulline), and to no structure (21% homocitrulline) (Fig. 7B). Likewise, with myoglobin, the alpha -helical content was reduced from ~70% to 60% (2% homocitrulline), ~15% (7% homocitrulline), and to <10% (10% homocitrulline) (Fig. 7C). In this case, the loss of structure with retained heme group and disulfide bonds was similar to that seen upon denaturation in acid solutions (53, 55, 56).


Fig. 7. Insertion of homocitrullines also denatures proteins. CD spectra were taken of THH-8 (A), a synthetic copolymer polypeptide (B), and myoglobin (C) after reaction with cyanate to convert up to 90% of lysines to homocitrullines. The numbers refer to the degrees of cyanate modification, as indicated under "Results and Discussion." In B the alpha -helical contents were estimated by computer analyses of the line shapes since the polypeptide is heterogeneous in molecular weight. In D, the estimated alpha -helical contents of the three proteins were plotted versus homocitrulline content (closed symbols). The data for THH-8 and citrulline (from Fig. 5B) are shown for comparison (open symbols).
[View Larger Version of this Image (20K GIF file)]


These data show that the insertion of homocitrulline even in low amounts begins to reduce the high alpha -helical contents of these proteins. Taken together, the degree of loss of structure correlates with the degree of modification (Fig. 7D). Indeed, comparison of the THH-8 data suggests that homocitrulline seems to be even more effective in unfolding of protein structure than citrulline. Therefore, these data support the concept that the ureido group of the citrulline or homocitrulline side chains promotes the observed interference in organized protein structure.

Substrate Structural Requirements for PAD Modification

While some information on the specificity of the PAD enzyme reaction has become available using arginine derivatives or short peptides (57), other data have been generated using model protein substrates, probably unrelated to in vivo substrates. For example, in soybean trypsin inhibitor, one arginine in its active site, located on an external loop, could be modified very rapidly (enzyme:substrate ratio of 1:50 in 10 min) (15), while nine others could be converted more slowly within 5 h (57). However, in mouse plasma trypsin inhibitor, which is largely alpha -helical in structure, the reaction proceeds at a rate one-tenth that for soybean trypsin inhibitor (15, 16). On the other hand deimination of IF protein chains occurs only in the non-alpha -helical head and tail domains (18). Together with the present data on the natural substrates filaggrin and THH-8 (Figs. 1 and 3; Table I), these observations suggested that the PAD reaction may be dependent on substrate structure.

To explore this issue further, we examined the structural requirements of the PAD enzyme reaction with synthetic peptides of filaggrin, THH, and keratins 1 and 10 (Table I). Following deimination at an enzyme:arginine ratio of 1:40,000, the peptides were purified by HPLC, analyzed to determine their citrulline contents, and sequenced (Table I). In most cases the peptide peaks from the HPLC column became broader, suggesting a heterogeneous population of molecules with varying degrees of arginine modification. The mimetic filaggrin peptide of beta -turn structure was 95% deiminated, as for the same sequence in intact mouse filaggrin. In the keratin 10 1A peptide of alpha -helical structure, an average of 70% of the arginines were modified, of which the second arginine from the amino terminus and the arginine third from the carboxyl terminus were converted ~50%, while the two internal arginines were modified 85%, and the alpha -helical structure of the peptide was lost. Similarly, in the shorter alpha -helical keratin 1 1A peptide, the amino-terminal arginine was only slightly modified. By CD the longer natural and mimetic THH peptides were >90% alpha -helical, and thus are more closely related to the structure of THH-8. While their alpha -helical structures were lost, the degrees of modification of the arginines varied widely. The amino-terminal arginine was not modified at all; most single arginines were completely modified; a single arginine followed by glutamic acid was modified only <10%; a single arginine followed by an aspartic acid residue was completely modified; and in the cases of two consecutive arginines, the second was less modified. To address what happens when two consecutive arginines preceded a glutamic acid, a mimetic THH peptide showed that the first was modified 70% and the second 50% (Table I). In general these data are highly comparable with those obtained for the same sequences in THH-8. By CD, the short THH peptide 5 had no organized structure in solution. The first arginine was partly modified; the second and third arginines were >90% modified; but the fourth arginine, followed by a glutamic acid residue, was significantly modified to 60-80%, to a much higher degree than in THH-8 or the two longer synthetic peptides.

Altogether, the present data accumulated from mouse filaggrin, human THH-8, and synthetic mimetic peptides show that arginines located near the amino terminus are poorly modified, arginines in highly alpha -helical protein structures are only slowly modified to near completion, and arginines in proteins of little structural order are rapidly modified to near completion. However, a single arginine followed by a glutamic acid residue is only poorly modified in an alpha -helical protein, but significantly modified in proteins of low structural order; in the rare cases of two consecutive arginines, the first was always modified to a greater extent than the second arginine. Thus the PAD reaction is dependent on both substrate structure and precise sequence around the arginine residues.

Concluding Remarks

The present studies have identified several important properties of the PAD enzyme. First, in general, proteins such as filaggrin having only a simple beta -turn secondary structure were quickly and quantitatively modified, while those with high alpha -helical contents were modified more slowly. Second, certain sequence preferences were identified. Thus the activity of the PAD enzyme is markedly affected by both substrate structure and substrate sequence in the vicinity of the arginines. Third, of likely significant biological importance, the present data show that the structural properties of the natural substrates THH and filaggrin are changed on extensive PAD modification. Modification of sufficient arginines to introduce a net citrulline content of <= 5% begins to disorder organized protein structures, and a net content of >= 10% causes loss of structure (Figs. 5 and 6). This may be attributable to the ureido group of the citrulline, since a charged electron donor group is modified to an electron acceptor group. This would be expected to interfere with the stabilization of H bonds and is no longer able to form ionic bonds. Chemical modification of lysines to homocitrullines may disorder organized protein structures in the same way (Fig. 7). The unfolding of filaggrin and THH by PAD in the skin would be expected to significantly alter their interactions with IF and transglutaminases (22, 26, 36, 58, 59), questions for which additional experiments will now be required.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Present address: Dept. of Dermatology, Chonnam University Hospital, Kwangju City 50-190, Republic of Korea.
   To whom all correspondence should be addressed: National Institutes of Health, Bldg. 6, Rm. 425, 9000 Rockville Pike, Bethesda, MD 20892-2755. Tel.: 301-496-1578; Fax: 301-402-2886; E-mail: pemast{at}helix.nih.gov.
1   The abbreviations used are: PAD, peptidylarginine deiminase; IF, intermediate filament(s); PAGE, polyacrylamide gel electrophoresis; THH, trichohyalin; THH-8, domain 8 of human trichohyalin; HPLC, high performance liquid chromatography; PTH, phenylthiohydantoin; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

Acknowledgments

We are indebted to Drs. A. Chrambach, A. Finazzi-Agrò, P. McPhie, M. Paci, and D. Parry for advice concerning the anomalous gel migration and structural properties of PAD-modified proteins. We thank Drs. E. Candi and B. Ciani for numerous helpful suggestions and encouragement, G. Poy for the synthesis of the oligonucleotides and most of the peptides used in this work, and W. Idler for technical assistance.


REFERENCES

  1. Rogers, G. E. (1964) in The Epidermis (Montagna, W., and Lobitz, W., eds), pp. 179-203, Academic Press, New York
  2. Rogers, G. E., Harding, H. W. J., and Llewellyn-Smith, I. J. (1977) Biochim. Biophys. Acta 495, 159-175 [Medline] [Medline] [Order article via Infotrieve]
  3. Rogers, G. E., and Taylor, L. D. (1977) in Advances in Experimental Medicine and Biology (Friedman, M., ed), Vol. 86A, pp. 283-294, Plenum Publishing Corp., New York
  4. Kubilus, J., Waitkus, R. W., and Baden, H. P. (1980) Biochim. Biophys. Acta 615, 246-251 [Medline] [Medline] [Order article via Infotrieve]
  5. Fujisaki, M., and Sugawara, K. (1981) J. Biochem. (Tokyo) 89, 257-263 [Medline] [Abstract/Free Full Text]
  6. Takahara, H., Oikawa, Y., and Sugawara, K. (1983) J. Biochem. (Tokyo) 94, 1945-1953 [Medline] [Abstract/Free Full Text]
  7. Kubilus, J., and Baden, H. (1983) Biochim. Biophys. Acta 745, 285-291 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  8. Watanabe, K., Akiyama, K., Hikichi, K., Ohtsuka, R., Okuyama, A., and Senshu, T. (1988) Biochim. Biophys. Acta 966, 375-383 [Medline] [Medline] [Order article via Infotrieve]
  9. Takahara, H., Tsuchida, M., Kusubata, M., Akutsu, K., Tagami, S., and Sugawara, K. (1989) J. Biol. Chem. 264, 13361-13368 [Medline] [Abstract/Free Full Text]
  10. Terakawa, H., Takahara, H., and Sugawara, K. (1991) J. Biochem. (Tokyo) 110, 661-666 [Medline] [Abstract/Free Full Text]
  11. Watanabe, K., and Senshu, T. (1989) J. Biol. Chem. 264, 15255-15260 [Medline] [Abstract/Free Full Text]
  12. Tsuchida, M., Takahara, H., Minami, N., Arai, T., Kobayashi, Y., Tsujimoto, H., Fukazawa, C., and Sugawara, K. (1993) Eur. J. Biochem. 215, 677-685 [Medline] [Medline] [Order article via Infotrieve]
  13. Tsuchida, M., Minami, N., Tsujimoto, H., Fukazawa, C., Takahara, H., and Sugawara, K. (1991) Agric. Biol. Chem. 55, 295-297 [Medline] [Medline] [Order article via Infotrieve]
  14. Nishijyo, T., Kawada, A., Shiraiwa, M., and Takahara, H. (1995) J. Invest. Dermatol. 104, 577
  15. Takahara, H., Okamoto, H., and Sugawara, K. (1985) J. Biol. Chem. 260, 8378-8383 [Medline] [Abstract/Free Full Text]
  16. Takahara, H., and Sugawara, K. (1987) Agric. Biol. Chem. 51, 1657-1664
  17. Steinert, P. M., and Idler, W. W. (1979) Biochemistry 18, 5664-5669 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  18. Inagaki, M., Takahara, H., Nishi, Y., Sugawara, K., and Sato, C. (1989) J. Biol. Chem. 264, 18119-18127 [Medline] [Abstract/Free Full Text]
  19. Senshu, T., Akiyama, K., Kanm, S., Asaga, H., Ishigami, A., and Manabe, M. (1995) J. Invest. Dermatol. 105, 163-169 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  20. Steinert, P. M., Cantieri, J. S., Teller, D. C., Lonsdale-Eccles, J. D., and Dale, B. A. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 4097-4101 [Medline] [Abstract/Free Full Text]
  21. Mack, J. W., Steven, A. C., and Steinert, P. M. (1993) J. Mol. Biol. 232, 50-66 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  22. Harding, C. R., and Scott, I. R. (1983) J. Mol. Biol. 170, 651-673 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  23. Auber, L. (1952) Trans. R. Soc. Edinb. 62, 191-201
  24. Birbeck, M. S. C., and Mercer, E. H. (1957) J. Biophys. Biochem. Cytol. 3, 223-230 [Abstract/Free Full Text]
  25. Rothnagel, J. A., and Rogers, G. E. (1986) J. Cell Biol. 102, 1419-1429 [Medline] [Abstract/Free Full Text]
  26. O'Guin, W. M., Sun, T.-T., and Manabe, M. (1992) J. Invest. Dermatol. 98, 24-32 [CrossRef][Medline] [Order article via Infotrieve]
  27. O'Keefe, E. J., Hamilton, E. H., Lee, S.-C., and Steinert, P. M. (1993) J. Invest. Dermatol. 101, 65S-71S [CrossRef]
  28. Manabe, M., and O'Guin, W. M. (1994) Differentiation 58, 65-75 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  29. Fietz, M. J., McLaughlan, C. J., Campbell, M. T., and Rogers, G. E. (1993) J. Cell Biol. 21, 855-865
  30. Hamilton, E. H., Sealock, R., Wallace, N. R., and O'Keefe, E. J. (1992) J. Invest. Dermatol. 98, 881-889 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  31. Lee, S.-C., Kim, I.-G., Marekov, L. N., O'Keefe, E. J., Parry, D. A. D., and Steinert, P. M. (1993) J. Biol. Chem. 268, 12164-12176 [Medline] [Abstract/Free Full Text]
  32. Rogers, G. E. (1963) J. Histochem. Cytochem. 11, 700-706 [Abstract]
  33. Steinert, P. M., Harding, H. W. J., and Rogers, G. E. (1969) Biochim. Biophys. Acta 175, 1-9 [Medline] [Medline] [Order article via Infotrieve]
  34. Harding, H. W. J., and Rogers, G. E. (1971) Biochemistry 10, 624-630 [CrossRef][Medline] [Order article via Infotrieve]
  35. Harding, H. W. J., and Rogers, G. E. (1976) Biochim. Biophys. Acta 427, 315-324 [Medline] [Order article via Infotrieve]
  36. Steinert, P. M. (1978) Biochemistry 17, 5045-5052 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  37. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  38. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  39. Kim, S.-Y., Kim, I.-G., Chung, S.-I., and Steinert, P. M. (1994) J. Biol. Chem. 269, 27979-27986 [Medline] [Abstract/Free Full Text]
  40. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning:. A Laboratory Manual, 2nd Ed., pp. 17.36-17.44, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  41. Farnsworth, V., and Steinberg, K. (1993) Anal. Biochem. 215, 190-199 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  42. Stark, G. R. (1967) Methods Enzymol. 11, 590-594
  43. Rothnagel, J. A., and Steinert, P. M. (1990) J. Biol. Chem. 265, 1862-1865 [Medline] [Abstract/Free Full Text]
  44. Rickwood, D. (1981) Gel Electrophoresis of Proteins: A Practical Approach, IRL Press, Washington, D.C.
  45. Marquesee, S., and Baldwin, R. L. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8898-8902 [Abstract/Free Full Text]
  46. Reynolds, J. A., and Tanford, C. (1970) J. Biol. Chem. 245, 5161-5165 [Medline] [Abstract/Free Full Text]
  47. Takagi, T., Tsujii, K., and Shirahama, K. (1975) J. Biochem. (Tokyo) 77, 939-947 [Medline] [Abstract/Free Full Text]
  48. Cohen, L. H., and Gotchel, B. V. (1971) J. Biol. Chem. 246, 1841-1848 [Medline] [Abstract/Free Full Text]
  49. Panyim, S., and Chalkley, R. (1971) J. Biol. Chem. 246, 7557-7560 [Medline] [Abstract/Free Full Text]
  50. Tung, J.-S., and Knight, C. A. (1971) Biochem. Biophys. Res. Commun. 42, 1117-1121 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  51. Noel, D., Nikaidy, K., and Ames, G. F.-L. (1979) Biochemistry 18, 4159-4165 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  52. Santucci, R., Brunori, M., and Ascoli, F. (1987) Biochim. Biophys. Acta 914, 185-189 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  53. Goto, Y., Calciano, L. J., and Fink, A. L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 573-577 [Medline] [Abstract/Free Full Text]
  54. Mei, G., Rosato, N., Silva, N., Rusch, R., Gratton, E., Savini, I., and Finazzi-Agrò, A. (1992) Biochemistry 31, 7224-7230 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  55. Breslow, E., Beychok, D., Hardman, K. D., and Gurd, F. R. N. (1965) J. Biol. Chem. 240, 304-309 [Free Full Text]
  56. Hughson, F. M., Wright, P. E., and Baldwin, R. L. (1990) Science 249, 1544-1548 [Medline] [Abstract/Free Full Text]
  57. Nomura, K. (1992) Arch. Biochem. Biophys. 293, 362-369 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  58. Candi, E., Melino, G., Mei, G., Tarcsa, E., Chung, S.-I., Marekov, L. N., and Steinert, P. M. (1995) J. Biol Chem. 270, 26382-26390 [JBC][Medline] [Abstract/Free Full Text]
  59. Steinert, P. M., and Marekov, L. N. (1995) J. Biol. Chem. 270, 17702-17711 [JBC][Medline] [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Y. Kamata, A. Taniguchi, M. Yamamoto, J. Nomura, K. Ishihara, H. Takahara, T. Hibino, and A. Takeda
Neutral Cysteine Protease Bleomycin Hydrolase Is Essential for the Breakdown of Deiminated Filaggrin into Amino Acids
J. Biol. Chem., May 8, 2009; 284(19): 12829 - 12836.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. Sandilands, C. Sutherland, A. D. Irvine, and W. H. I. McLean
Filaggrin in the frontline: role in skin barrier function and disease
J. Cell Sci., May 1, 2009; 122(9): 1285 - 1294.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
H. Uysal, R. Bockermann, K. S. Nandakumar, B. Sehnert, E. Bajtner, A. Engstrom, G. Serre, H. Burkhardt, M. M.G.M. Thunnissen, and R. Holmdahl
Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis
J. Exp. Med., February 16, 2009; 206(2): 449 - 462.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
B. Jang, E. Kim, J.-K. Choi, J.-K. Jin, J.-I. Kim, A. Ishigami, N. Maruyama, R. I. Carp, Y.-S. Kim, and E.-K. Choi
Accumulation of Citrullinated Proteins by Up-Regulated Peptidylarginine Deiminase 2 in Brains of Scrapie-Infected Mice: A Possible Role in Pathogenesis
Am. J. Pathol., October 1, 2008; 173(4): 1129 - 1142.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
M. Nakayama-Hamada, A. Suzuki, H. Furukawa, R. Yamada, and K. Yamamoto
Citrullinated Fibrinogen Inhibits Thrombin-catalysed Fibrin Polymerization
J. Biochem., September 1, 2008; 144(3): 393 - 398.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Kizawa, H. Takahara, H. Troxler, P. Kleinert, U. Mochida, and C. W. Heizmann
Specific Citrullination Causes Assembly of a Globular S100A3 Homotetramer: A PUTATIVE Ca2+ MODULATOR MATURES HUMAN HAIR CUTICLE
J. Biol. Chem., February 22, 2008; 283(8): 5004 - 5013.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Arita, T. Shimizu, H. Hashimoto, Y. Hidaka, M. Yamada, and M. Sato
Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4
PNAS, April 4, 2006; 103(14): 5291 - 5296.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. van Gaalen, A. Ioan-Facsinay, T. W. J. Huizinga, and R. E. M. Toes
The Devil in the Details: The Emerging Role of Anticitrulline Autoimmunity in Rheumatoid Arthritis
J. Immunol., November 1, 2005; 175(9): 5575 - 5580.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Chapuy-Regaud, M. Sebbag, D. Baeten, C. Clavel, C. Foulquier, F. De Keyser, and G. Serre
Fibrin Deimination in Synovial Tissue Is Not Specific for Rheumatoid Arthritis but Commonly Occurs during Synovitides
J. Immunol., April 15, 2005; 174(8): 5057 - 5064.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
X. Chang, R. Yamada, A. Suzuki, T. Sawada, S. Yoshino, S. Tokuhiro, and K. Yamamoto
Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis
Rheumatology, January 1, 2005; 44(1): 40 - 50.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
E R Vossenaar, T R D Radstake, A van der Heijden, M A M van Mansum, C Dieteren, D-J de Rooij, P Barrera, A J W Zendman, and W J van Venrooij
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages
Ann Rheum Dis, April 1, 2004; 63(4): 373 - 381.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. M. Steinert, D. A. D. Parry, and L. N. Marekov
Trichohyalin Mechanically Strengthens the Hair Follicle: MULTIPLE CROSS-BRIDGING ROLES IN THE INNER ROOT SHEATH
J. Biol. Chem., October 17, 2003; 278(42): 41409 - 41419.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
S. Bas, T. V. Perneger, M. Seitz, J.-M. Tiercy, P. Roux-Lombard, and P. A. Guerne
Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors
Rheumatology, July 1, 2002; 41(7): 809 - 814.
[Abstract] [Full Text] [PDF]


Home page
CROBMHome page
R. B. Presland and B. A. Dale
Epithelial Structural Proteins of the Skin and Oral Cavity: Function in Health and Disease
Critical Reviews in Oral Biology & Medicine, January 1, 2000; 11(4): 383 - 408.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Nakashima, T. Hagiwara, A. Ishigami, S. Nagata, H. Asaga, M. Kuramoto, T. Senshu, and M. Yamada
Molecular Characterization of Peptidylarginine Deiminase in HL-60 Cells Induced by Retinoic Acid and 1alpha ,25-Dihydroxyvitamin D3
J. Biol. Chem., September 24, 1999; 274(39): 27786 - 27792.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. M. Steinert, Y.-H. Chou, V. Prahlad, D. A. D. Parry, L. N. Marekov, K. C. Wu, S.-I. Jang, and R. D. Goldman
A High Molecular Weight Intermediate Filament-associated Protein in BHK-21 Cells Is Nestin, a Type VI Intermediate Filament Protein. LIMITED CO-ASSEMBLY IN VITRO TO FORM HETEROPOLYMERS WITH TYPE III VIMENTIN AND TYPE IV alpha -INTERNEXIN
J. Biol. Chem., April 2, 1999; 274(14): 9881 - 9890.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Candi, E. Tarcsa, W. W. Idler, T. Kartasova, L. N. Marekov, and P. M. Steinert
Transglutaminase Cross-linking Properties of the Small Proline-rich 1 Family of Cornified Cell Envelope Proteins. INTEGRATION WITH LORICRIN
J. Biol. Chem., March 12, 1999; 274(11): 7226 - 7237.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Girbal-Neuhauser, J.-J. Durieux, M. Arnaud, P. Dalbon, M. Sebbag, C. Vincent, M. Simon, T. Senshu, C. Masson-Bessiere, C. Jolivet-Reynaud, et al.
The Epitopes Targeted by the Rheumatoid Arthritis-Associated Antifilaggrin Autoantibodies are Posttranslationally Generated on Various Sites of (Pro)Filaggrin by Deimination of Arginine Residues
J. Immunol., January 1, 1999; 162(1): 585 - 594.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. M. Steinert, T. Kartasova, and L. N. Marekov
Biochemical Evidence That Small Proline-rich Proteins and Trichohyalin Function in Epithelia by Modulation of the Biomechanical Properties of Their Cornified Cell Envelopes
J. Biol. Chem., May 8, 1998; 273(19): 11758 - 11769.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Tarcsa, L. N. Marekov, J. Andreoli, W. W. Idler, E. Candi, S.-I. Chung, and P. M. Steinert
The Fate of Trichohyalin. SEQUENTIAL POST-TRANSLATIONAL MODIFICATIONS BY PEPTIDYL-ARGININE DEIMINASE AND TRANSGLUTAMINASES
J. Biol. Chem., October 31, 1997; 272(44): 27893 - 27901.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tarcsa, E.
Right arrow Articles by Steinert, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarcsa, E.
Right arrow Articles by Steinert, P. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement